As discussed, GLP-1 therapy creates a real risk of B12 depletion over time
Brito-da-Costa AM, Dias-da-Silva D, Gomes NGM, Dinis-Oliveira RJ, Madureira-Carvalho
Clinical Effectiveness: SURMOUNT-1 Trial (Tirzepatide 15 mg): Duration: 72 weeks Participants: 2,539 adults with obesity Average Weight Loss: 22.5% of body weight 10 mg Dose: 21.4% weight loss 5 mg Dose: 15.0% weight loss Placebo: 2.4% weight loss 5% Weight Loss: 96% of participants 10% Weight Loss: 89% of participants 15% Weight Loss: 78% of participants 20% Weight Loss: 63% of participants This is the best weight loss result ever achieved with medication in clinical trials
For regulators, its a warning sign - proof that the digital health industry is moving faster than the frameworks built to govern it
It calls for urgent action on manufacturing, affordability and system readiness to meet global needs. The new guidance signals that GLP-1s for obesity treatment are moving into the mainstream of health care, Louis Aronne, an obesity researcher at Weill Cornell Medicine, tells Dan Vergano at Scientific American
At this concentration: 1mg dose = 0.03mL (3 units on U-100 insulin syringe) 2mg dose = 0.06mL (6 units) 3mg dose = 0.09mL (9 units) 5mg dose = 0.15mL (15 units) You can adjust concentration by adding more or less water